Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis
PLOS One · 11.06.2026 · 21 (6) · e0351029
DOI: 10.1371/journal.pone.0351029 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.06.2026. Verfasst von Shuo Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China. Hauptthemen laut MEDLINE: Bevacizumab, Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
From China’s healthcare perspective, this analysis compared the cost-effectiveness of Atezolizumab in combination with Bevacizumab and chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer.
Methods
A Markov model was developed to track patients’ transitions over 3-week cycles and evaluate the health and economic outcomes over a 10-year horizon for the two competing treatments. The survival data were gathered from the BEATcc trial, and cost and utility values were obtained from the published studies. Total costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were the model outcomes. Sensitivity analyzes were performed to examine the robustness of the model results.
Results
In the base case, atezolizumab plus bevacizumab and chemotherapy yielded a marginal cost of $233,602.51 and an additional 0.54 QALYs, resulting in an ICER of $432,597.24 per additional QALY gained, which exceeded the willingness-to-pay (WTP) threshold of $36,859 in China. Sensitivity analyzes confirmed the robustness of the model outcomes.
Conclusions
Atezolizumab plus bevacizumab and chemotherapy was not a cost-effective treatment for patients with metastatic, persistent, or recurrent cervical cancer compared with bevacizumab plus chemotherapy from the perspective of the Chinese health-care system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
- Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
- Development Planning Division, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
- Development Planning Division, The Second Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
ORCID-Profile: Shuo Yang, Zhenhua Pan
Zitieren
APA
Yang, S., Hou, Y., Wang, X., Kang, S., & Pan, Z. (2026). Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLOS One, 21(6), e0351029. https://doi.org/10.1371/journal.pone.0351029
Vancouver
Yang S, Hou Y, Wang X, Kang S, Pan Z. Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLOS One. 2026;21(6):e0351029. doi:10.1371/journal.pone.0351029
BibTeX
@article{Yang2026,
author = {Yang, Shuo and Hou, Yibing and Wang, Xiaohui and Kang, Shuo and Pan, Zhenhua},
title = {Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0351029},
doi = {10.1371/journal.pone.0351029}
}
EUVIMED